4/24
10:15 am
nuvb
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Medium
Report
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/24
10:01 am
nuvb
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Low
Report
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
4/10
04:09 pm
nuvb
Nuvation Bio Completes Acquisition of AnHeart Therapeutics [Yahoo! Finance]
Medium
Report
Nuvation Bio Completes Acquisition of AnHeart Therapeutics [Yahoo! Finance]
4/10
04:01 pm
nuvb
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Medium
Report
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
3/31
10:00 am
nuvb
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]
Neutral
Report
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]
3/31
04:55 am
nuvb
Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal [Seeking Alpha]
Neutral
Report
Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal [Seeking Alpha]
3/28
08:09 am
nuvb
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer [Yahoo! Finance]
Medium
Report
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer [Yahoo! Finance]
3/28
08:07 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $5.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $5.00 to $8.00. They now have a "buy" rating on the stock.
3/28
08:00 am
nuvb
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
Medium
Report
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
3/27
08:07 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $1.40.
High
Report
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $1.40.
3/26
12:59 pm
nuvb
VERI, CHEK and CZOO among mid-day movers [Seeking Alpha]
Low
Report
VERI, CHEK and CZOO among mid-day movers [Seeking Alpha]
3/26
08:13 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.
High
Report
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.
3/25
09:05 am
nuvb
Nuvation Bio falls after AnHeart Therapeutics acquisition news [Seeking Alpha]
High
Report
Nuvation Bio falls after AnHeart Therapeutics acquisition news [Seeking Alpha]
3/25
07:05 am
nuvb
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction [Yahoo! Finance]
Neutral
Report
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction [Yahoo! Finance]
3/25
07:00 am
nuvb
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Low
Report
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
3/14
04:21 pm
nuvb
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors [Yahoo! Finance]
Medium
Report
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors [Yahoo! Finance]
3/14
04:05 pm
nuvb
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
Medium
Report
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
3/8
02:11 pm
nuvb
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know [Yahoo! Finance]
Low
Report
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know [Yahoo! Finance]
3/7
08:02 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $4.50 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $4.50 to $5.00. They now have a "buy" rating on the stock.
3/1
09:03 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
2/29
04:13 pm
nuvb
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
2/29
04:01 pm
nuvb
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
High
Report
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/17
07:23 am
nuvb
Owning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB), [Yahoo! Finance]
Low
Report
Owning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB), [Yahoo! Finance]